Q-omics provides the consensus-scored MTRF1 profile across patient tissues and cancer cell-line models. MTRF1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MTRF1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MTRF1 RNA expression shows 20,808 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, HNSC, and ACC as cancer lineages where MTRF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRF1 survival associations across molecular data types. MTRF1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRF1 RNA expression–survival associations across cancer types. High MTRF1 expression shows unfavorable associations in UVM, CESC, LGG, ACC and DLBC, but favorable associations in UCEC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MTRF1 RNA expression.
This table summarizes MTRF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTRF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRF1 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, COAD, BLCA and STAD. The HNSC box plot shows higher MTRF1 RNA expression in tumor versus normal tissue (log2 FC = +0.500, t-test p < 0.001).
This table shows molecular features associated with MTRF1 in patient tissues and cancer cell lines. In patient samples, MTRF1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTRF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
